Failures to implement recommendations from previous incidents and poor communication led to unrelated errors including two non-fatal drug overdoses at the Alberta Children's Hospital, a review has concluded.

Failures to implement recommendations from previous incidents and poor communication led to unrelated errors - including two non-fatal drug overdoses - at the Alberta Children's Hospital, a review has concluded.

Failures to implement recommendations from previous incidents and poor communication led to unrelated errors - including two non-fatal drug overdoses - at the Alberta Children's Hospital, a review has concluded.

ATHENS TOWNSHIP — Two more individuals have been arrested on warrants obtained by the Bradford County Drug Task Force following the Investigation into illegal drug transactions in the area.

RALEIGH, N.C.----BioDelivery Sciences International, Inc. announced today that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference at The Ritz-Carlton, Laguna Niguel in Dana Point, California.

PHOENIX, March 9 /PRNewswire/ -- INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray (SL Spray) technology to treat breakthrough cancer pain.

SPRINGFIELD The medical license of a doctor with privileges at Mercy Medical Center and Baystate Medical Center has been suspended after a state board determined that he practiced medicine while impaired by drugs.

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference ...

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. Â All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity ...

MOUNTAIN VIEW, Calif., March 8 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the fourth quarter and year ended December 31, 2009 and provided a general corporate update.